

Autonomous AI Decision Systems for Resilient United States Pharmaceutical Supply Chains

Ankit Sharma^{1*}, Adarsh Srivastava², Priyanshi Joshi³, Vinisha Parswani⁴

Independent Researcher, United States of America.

*Corresponding Author

Ankit Sharma

Email: ankit.buffalo@gmail.com

Article History

Received: 05.01.2025

Accepted: 03.03.2025

Published: 24.04.2025

Abstract: U.S. pharmaceutical supply chains are increasingly exposed to disruption risks including manufacturing downtime, logistics failures, demand surges, and regulatory bottlenecks. These disruptions can propagate rapidly and result in drug shortages, delayed patient access, and elevated operational costs. This study proposes and evaluates an autonomous AI decision system that integrates real-time signals from manufacturing, inventory, logistics, and quality operations to reduce disruption detection time and accelerate recovery actions. The proposed architecture combines predictive analytics for early disruption sensing with reinforcement learning-based decision policies for adaptive response, including production resequencing, inventory rebalancing, and dynamic shipment rerouting. A bounded autonomy governance layer is incorporated to ensure that high-impact decisions (e.g., batch release exceptions, cold-chain risk decisions, compliance deviations) are escalated to human experts for validation under FDA-aligned constraints. The approach is assessed using scenario-based simulation experiments representing three common disruption categories in pharmaceutical supply chains: (i) production delays, (ii) transportation failures, and (iii) regulatory/quality constraints. Results demonstrate that autonomous decision execution improves resilience outcomes by shortening the sense–decide–act cycle, reducing stockout exposure windows, improving on-time delivery performance, and maintaining compliance through structured human-in-the-loop approval gates. The findings support a practical roadmap for deploying safe, explainable, and regulation-aware autonomy in U.S. pharmaceutical supply networks. All evaluations are conducted under controlled scenario-based simulation settings to ensure repeatability and comparability between baseline and autonomous policies.

Keywords: Autonomous AI, Pharmaceutical Supply Chains, Decision Systems, Supply Chain Resilience, Drug Shortages, Real-Time Data Analytics, Logistics Optimization, Regulatory Compliance.

Cite this article:

Sharma, A., Srivastava, A., Joshi, P., Parswani, V., (2025). Autonomous AI Decision Systems for Resilient United States Pharmaceutical Supply Chains. *ISAR Journal of Science and Technology*, 3(4), 53-66.



1.0 Introduction

The pharmaceutical sector in the United States is a crucial sector of the global healthcare service, and this sector handles the production and distribution of life-saving drugs on time. Pharmaceutical supply chains can be described as complicated networks of numerous stakeholders that include manufacturers, distributors, wholesalers, and healthcare providers. Nevertheless, such supply chains are vulnerable to disruptions that have the potential to affect the supply of the necessary medications in a negative way. The operational aspects, including production delays, transportation delays, regulatory issues, and unforeseen demand spikes may lead to high levels of operational inefficiency, thus impacting patient care.

This has been necessitated by the current disruptions in the world caused by the COVID-19 pandemic that demonstrated the susceptibility of pharmaceutical supply chains. During such crises, pharmaceutical companies are finding it difficult to operate at a relatively steady state, which is why the classical concepts of supply chains are no longer able to address the increased demands on drugs and vaccines.

To cope with such issues and improve the resilience of supply chains, the pharmaceutical industry is resorting to innovations, especially to artificial intelligence (AI) and machine learning. Autonomous AI decision systems, which are based on real-time information at different points of the supply chain system have demonstrated tremendous potential in revolutionizing the supply chain management system. Such AI will be able to detect possible disruptions on its own, anticipate risks in the future, and make amends in real-time to avoid delays or shortages. Due to constant data analysis conducted on manufacturing, quality control and logistics, the AI could offer actionable data that would help prevent a problem before it would get out of control, like rerouting cargo or shifting manufacturing to meet demand.

As opposed to traditional software systems that are based on a predefined set of rules or human intervention, autonomous AI systems are able to adjust their supply chain state according to the dynamic changes without human interventions. Such systems may provide drastic benefits in comparison to the old ways of working, such as less downtime, efficient inventory management, and efficient decision-making. Nonetheless, the introduction of autonomous AI into pharmaceutical supply chains leads to some concerns regarding the compliance with regulations and medical products safety. Although AI may be used to streamline logistics and operations, the system needs human controls that ensure that the system complies with industry regulations (including those introduced by the U.S. Food and Drug Administration (FDA)).

The integration of autonomous AI in pharmaceutical supply chains can potentially result in stronger, more resilient supply chain structures capable of withstanding international disruptions and making the necessary medications available. In this study, the authors examine the opportunities of autonomous AI-based decisions systems to be successfully implemented into pharmaceutical supply chains of the U.S. and the ways in which the collaboration between AI-based and human-centered knowledge-sharing systems can be used to ensure regulatory adherence and safety.

This study contributes to the pharmaceutical supply chain resilience literature in four ways mentioned below.

Key Contributions:

- **C1:** Proposes an end-to-end autonomous AI decision architecture integrating manufacturing, inventory, logistics, and quality signals into a single disruption-response loop.
- **C2:** Introduces a bounded autonomy governance mechanism tailored for U.S. pharmaceutical supply chains, distinguishing low-risk automated actions from compliance-critical decisions requiring human approval.
- **C3:** Operationalizes resilience evaluation through disruption-specific KPIs including detection time, recovery time, stockout exposure, on-time delivery, and compliance approval rate.
- **C4:** Evaluates system behavior through scenario-based simulations representing production delays, logistics disruptions, and regulatory/quality holds.

2.0 Literature review

A. Pharmaceutical Supply Chain Problems.

Pharmaceutical supply chains have many challenges which can greatly affect the supply of the important drugs. Such issues are delays in the production process, shortages in supplies, distribution interference that may occur due to unforeseen factors, including natural disasters or pandemics. Pharmaceutical supply chains are global, and, thus, creating complexities, it becomes challenging to operate and provide drugs on time. To illustrate, the COVID-19 pandemic highlighted the weaknesses of the pharmaceutical distribution systems and showed how the lack of effectiveness of logistics and regulatory bottlenecks could help to prevent access to life-saving vaccines and drugs.

Furthermore, pharmaceutical firms must always be on their toes to comply with regulations, deal with up and down demand as well as uphold quality at different points of the supply chain. Consequently, the conventional supply chain management systems that are highly people-intensive and involve pre-programmed processes cannot respond expeditiously to the dynamic disruptions. These restrictions have contributed to the increased interest in harnessing the power of cutting-edge technologies, such as artificial intelligence (AI), to enhance the effectiveness and the robustness of pharmaceutical supply chains.

B. AI in Healthcare Logistics

AI has already been demonstrated to be an effective tool in streamlining all kinds of logistic systems, and the use of AI in healthcare supply chains is not an exception. AI has shown itself to be efficient and cost reduction in numerous industries as a result of predictive analytics and demand forecasting. In the medical sector, AI-based decision-making systems can be used to predict possible disruptions of the supply chain by processing big data produced through manufacturing, quality management, and logistics.

As an example, AI would be able to forecast possible shortage of drugs based on the trends of production, past sales data, and availability of raw materials. One can also predict transportation bottleneck delays or regulatory approvals using machine learning

models, and then use this prediction to respond proactively, e.g. by changing the production schedule or rerouting shipments. This predictive feature is particularly important when applied to the pharmaceutical supply chain, where time-sensitive in the health and safety of patients.

C. Self-Governing Decision-Making Supply Chains.

Autonomous AI systems go a step ahead and leverage the capabilities of AI to predict disruptions but go further in making their own decisions and acting independently, off the oversight of the human. These systems are capable of learning using data and adjusting to dynamism in the conditions they are used in, allowing them to maximize the processes of a supply chain in real-time. Autonomous AI in the pharmaceutical supply chains can handle the task of adjusting the inventory levels, diversion of shipments, or altering production plans based on real-time data. This degree of independence enables quicker decision-making, which is necessary when dealing with crisis situations when delays can be disastrous.

Autonomous AI application in supply chains has been considered in a range of industries, such as logistics and manufacturing. Nonetheless, AI introduction to pharmaceutical supply chains comes with specific hardships because of the highly regulated industry and the requirement to adhere to the safety standards strictly. Even in the face of these issues, the early studies suggest that the use of autonomous systems might lead to improved performance of the operational system and less chance of human decision-maker errors.

D. Regulatory and Compliance Considerations.

The ability to comply with the regulations is one of the biggest issues of autonomous AI implementation in pharmaceutical supply chains. The pharmaceutical industry has been regulated to an extent that there are stringent requirements outlined by the relevant bodies like the U.S Food and Drug Administration (FDA) to control the safety, effectiveness, and quality of medicines. These rules also address multiple sides of the supply chain such as manufacturing, storage, and transportation of pharmaceutical products.

Although autonomous AI systems have the potential to enhance operational efficiency greatly, there is still a need to have human

control over the decisions made by AI to ensure that they are adhering to these rules. As an example, AI-generated modifications to the production or distribution plans might require regulatory professionals to revise them and make sure that the modifications do not harm the product quality or the safety of the patients. The combination of AI and human professionals is essential to the preservation of the efficiency-compliance balance in the pharmaceutical supply chains.

E. Effect of AI on Supply Chain Resilience.

Autonomous AI could be integrated into pharmaceutical supply chains to promote resilience through improved response to interruptions by the systems. Pharmaceutical companies can become more responsive to the changes that the AIs-based decision-making systems will be able to predict and control before turning into full-scale crises. As a case in point, AI technology can predict possible bottlenecks or disruptions that could occur in the supply chain due to inaccessibility of raw materials, delays by regulations, and transport problems. These systems can minimize the effects of such disruptions on the supply of essential medicines by implementing proactive steps, including changing production times and re-shipping.

The studies about the effect of AI on the resilience of supply chains have demonstrated that AI applications are capable of enhancing responsiveness, decreasing downtimes, and maximization of resources allocation. It is likely that the application of AI in supply chains will result in an improved level of flexibility in the operations of the pharmaceutical company, which can afford to have drugs available despite the occurrence of unforeseen disruptions.

2.1 Summary of Prior Work and Identified Gap

Table 1 shows that prior studies largely emphasize prediction, analytics, or resilience strategy design, while fewer works operationalize end-to-end autonomous execution. Moreover, governance mechanisms that explicitly separate low-risk automated actions from compliance-critical decisions remain limited in the pharmaceutical supply chain context. This study addresses this gap by integrating autonomous decision execution with bounded autonomy governance and KPI-driven evaluation.

Table 1. Comparison of Prior Work vs. This Study (Autonomous AI for Pharma Supply Chain Resilience)

Author (Year)	Focus	Autonomous Execution	Governance	Evaluation
Christopher & Peck (2004)	Supply chain resilience foundations and capabilities	No	No	Conceptual framework
Sheffi (2005)	Enterprise resilience and disruption recovery strategy	No	No	Case-based insights
Tang (2006)	Robust strategies to mitigate supply chain disruptions	No	No	Conceptual + managerial
Ponomarov & Holcomb (2009)	Definition and measurement of supply chain resilience	No	No	Conceptual synthesis
Pettit, Fiksel, & Croxton (2010)	Resilience capability–vulnerability framework	No	No	Conceptual framework

Blackhurst, Dunn, & Craighead (2011)	Global supply resiliency and risk drivers	No	Partial	Empirical framework
Waller & Fawcett (2013)	Predictive analytics and big data for SCM decision-making	No	Partial	Conceptual + industry view
Ivanov, Sokolov, & Dolgui (2014)	Ripple effect disruption propagation in supply networks	No	No	Analytical modeling
Ambulkar, Blackhurst, & Grawe (2015)	Measuring firm resilience and disruption response capability	No	Partial	Empirical scale validation
Ventola (2011)	U.S. drug shortages: causes and impacts	No	No	Healthcare commentary
Fox, Sweet, & Jensen (2014)	Drug shortages as healthcare crisis and mitigation needs	No	No	Healthcare review
Iyengar, Hedman, Forte, & Hill (2016)	Medicine shortages: causes and mitigation strategies	No	No	Review/commentary
Snyder et al. (2016)	Optimization models for disruption management	Partial	No	Review + modeling
Ribeiro, Singh, & Guestrin (2016)	Explainable AI (LIME) for interpretable decisions	No	Yes	Algorithm + experiments
Doshi-Velez & Kim (2017)	Interpretability science for ML systems	No	Yes	Research agenda
Choi, Wallace, & Wang (2018)	Big data analytics in operations and SCM	No	Partial	Review
Sutton & Barto (2018)	Reinforcement learning foundations for sequential decisions	Yes (general)	No	Theoretical
Rahwan (2018)	Society-in-the-loop governance for AI systems	No	Yes	Conceptual governance
Kritzinger et al. (2018)	Digital twin foundations in manufacturing systems	Partial	Partial	Literature review
Ben-Daya, Hassini, & Bahroun (2019)	IoT-enabled supply chain visibility and control	Partial	Partial	Literature review
Dubey et al. (2020)	Analytics capability and operational flexibility	No	Partial	Empirical
Ivanov (2020)	Epidemic-driven disruption impact modeling (COVID-19)	No	No	Simulation
Shneiderman (2020)	Human-centered AI for safe, reliable systems	No	Yes	Conceptual
Ivanov & Dolgui (2021)	Ripple effect coping methods and resilience decision support	Partial	Partial	Review + implications
This Study	Autonomous AI decision system for resilient U.S. pharmaceutical supply chains with bounded autonomy governance	Yes	Yes	Scenario-based simulation + KPIs (30 runs)

3.0 Research Gap and Motivation

Prior research has established the value of analytics, AI, and digital technologies for improving supply chain visibility and responsiveness. However, two critical gaps remain for pharmaceutical supply chains. First, many AI-enabled supply chain studies focus on prediction and recommendation rather than safe autonomous execution, leaving limited guidance on how AI can act in real time under strict compliance constraints. Second, pharmaceutical environments require decision governance mechanisms that explicitly incorporate quality and regulatory

constraints (e.g., batch release rules, cold-chain integrity, deviation management), yet these constraints are often treated as external checks rather than embedded decision variables. This study addresses these gaps by proposing and evaluating a bounded autonomy decision system in which low-risk decisions can be executed autonomously while high-impact compliance decisions are routed through human validation workflows.

Accordingly, this study positions autonomous decision execution and compliance-aware governance as co-equal design requirements for resilient pharmaceutical supply chains.

3.1 Research Objectives and Questions.

A. Research Objectives

The main aim of the study is to determine the efficiency of autonomous AI decision systems in enhancing resilience and operational efficiency of pharmaceutical supply chains in the U.S. In particular, this study aims to:

Determine the success of autonomous AI in anticipating and controlling supply chain issues in pharmaceutical supply chains, including drug stock-outs, factory downtime, and traffic jams.

Discuss the applications of AI-based decision systems in autonomously optimizing such key processes as production scheduling, inventory, and shipment routing based on real-time information.

Examine how human supervision can be used to verify that the system is adhering to regulatory requirements, making sure that the activities of the independent AI system are within the FDA regulations and industry requirements.

Identify key barriers to implementing autonomous AI in regulated pharmaceutical supply chains, including data quality, interoperability constraints, system integration complexity, and governance readiness

B. Research Questions

The research questions addressed by this study are as follows:

To what extent are autonomous AI decision systems effective at forecasting and reducing disruption in pharmaceutical supply lines (e.g. production stoppages, drug shortages, and transport difficulties)?

How far can self-directed AI systems optimize supply chain functions including production planning, inventory control and shipment routing in the pharmaceutical industry?

How can human supervision be used to ensure that AI-based decisions are not taken out of regulatory framework, including the ones administered by the FDA, and will not impact patient safety or drug quality?

Which are the problems and restrictions of using autonomous AI systems in the pharmaceutical supply chain, in the context of integrating data, ethical compliance, and system adaptation?

Answering these research questions, the study will give a full picture of the potential, challenges, and practical implications of implementing autonomous AI systems in the pharmaceutical supply chains of the U.S.

3.2 Conceptual Model and Propositions

This study conceptualizes autonomous AI decision systems as an operational capability that improves supply chain resilience through faster disruption sensing, decision execution, and adaptive learning. The model assumes that resilience performance is enhanced when autonomous decisions are supported by (i) interoperable real-time data and (ii) bounded autonomy governance that ensures compliance alignment. Based on this logic, the study proposes:

P1: Autonomous AI decision systems reduce disruption detection time and recovery time compared to traditional human-driven decision cycles.

P2: Autonomous AI decision systems reduce stockout exposure windows and improve service performance (e.g., on-time delivery) during disruption events.

P3: Bounded autonomy governance improves compliance outcomes by increasing the percentage of high-impact decisions reviewed through human validation.

P4: The performance impact of autonomous AI is moderated by data interoperability and data latency, such that higher data quality and timeliness lead to stronger resilience gains.

4.0. Scope of Study

A. Scope of Study

This study examines to the pharmaceutical supply chains in the U.S. and how autonomous AI decision systems can be integrated into this environment. The research is restricted in the investigation of the possibilities of autonomous AI to anticipate and handle disruptions, streamline logistics, and keep in line with the regulatory requirements.

The important points of the research are:

Pharmaceutical Supply Chain Operations: This paper concentrates on the fundamental activities in the pharmaceutical supply chains which are production, inventory management, shipment, and quality assurance. These are the core functions of other roles that guarantee timely and efficient delivery of vital drugs to patients.

Autonomous AI Decision Systems: In this study, the researcher reviews AI systems that can make autonomous decisions, whereby the machine learning algorithms are used to optimize and control different steps of the supply chain. The system utilizes real-time data and past trends to forecast disruptions and manipulate operations in advance.

Regulatory Compliance: Due to the highly governed state of pharmaceutical industry, the research underscores the significance of considering that autonomous AI decisions do not conflict with FDA regulations and other industry standards. The AI decision making process incorporates human supervision mechanisms to authenticate critical decisions.

Challenges and Barriers: The paper will also handle the challenges and barriers to the implementation of autonomous AI systems, especially in a highly regulated sector such as the pharmaceutical industry. Such issues as the level of data quality, system integration, and compliance will find detailed discussion.

The study will not consider pharmaceutical supply chain beyond the U.S or other non-pharmaceutical industries, so that the study will not be broad-based, and thus, will be sufficiently focused on the unique needs and complexities of the U.S. pharmaceutical industry.

5.0. Theoretical Framework

A. Resilience Theory

The idea of resiliency is the focus of the current study because the aim is to increase the capacity of the pharmaceutical supply chain

to react to disruptions. According to the resilience theory, systems, such as the supply chain, can be made to not only absorb the shock, but also, they can restore their functionality to bounce back and cope with unexpected incidents. Within the pharmaceutical supply chains, resilience means the capacity to keep the constant availability of drugs in the case of disruption due to any reason such as the shortage of supplies, logistics breakdowns, or regulatory delays. This resilience can be strengthened by the autonomous AI decision systems to offer forecasts and real-time corrections to enable the system to adjust and reduce the effect of disruptions. This framework will be applied to determine the efficiency of autonomous AI in ensuring continuity of supply chains during crisis.

B. Technology Acceptance Model (TAM).

The Technology Acceptance Model (TAM) is applied in order to make sense of the way people reach the acceptance and usage of new technologies. TAM suggests that the perceived ease of use and

the perceived usefulness of technology are the most important determinants that contribute to technology acceptance. This model will assist in determining how the major stakeholders in the pharmaceutical industry such as the supply chain managers and the regulatory bodies will accept autonomous AI decision systems. With the help of TAM, the research will estimate the issues that determine the readiness of pharmaceutical companies to use AI technologies in their work and investigate possible obstacles to the use of these technologies, including trust, cost, and regulatory issues.

Figure 1 illustrates how external variables influence perceived usefulness and perceived ease of use, shaping stakeholder attitudes, behavioral intention, and actual system use. In this study, TAM is used to explain adoption readiness for autonomous AI decision systems among pharmaceutical supply chain managers, quality teams, and regulatory stakeholders.




Figure 1. Technology Acceptance Model (TAM) Applied to Autonomous AI Adoption in Pharmaceutical Supply Chains. (Source: Author's own illustration.)

C. Dynamic Capability Theory

Dynamic Capability Theory concentrates on how a firm can combine, create and restructure both internal and external capabilities in response to change environments that are rapidly evolving. The theory will be used to comprehend how the pharmaceutical firms can adjust to the fast-changing environment of the supply chain disruptions, using AI to reorganize their supply chains to address the emerging challenges. The idea of dynamic capabilities is consistent with the application of AI to create a more versatile, dynamic, and resilient supply chain that will react to unforeseen disruptions.

6.0 Methodology

The study is a mixed-methods study that combines both quantitative and qualitative methods to determine the performance of autonomous AI decision systems in improving the resilience and efficiency of U.S. pharmaceutical supply chains. The research is based on simulation-testing and real-world data of the different levels of the pharmaceutical supply chain, including manufacturing, logistic, inventory management, and quality control.

A. Data Collection

The information applied in this study was obtained at various phases of pharmaceutical supply networks, and it mainly concerned manufacturing, inventory management and logistics as

well as quality control. The information gathered involves both live and past information supplied by the supply chain to supply to the AI system to make predictive analytics and decisions.

The following were the sources of data collected:

Manufacturing data: The data on manufacturing rates, raw materials availability, and manufacturing schedules were obtained in manufacturing facilities.

Logistics information: GPS tracking and shipment tracking systems were used to obtain real-time logistics information, such as transportation, shipping route and delivery time.

Inventory data: Details about the quantity of inventory, replenishment schedules, and past demand were obtained through warehouse management systems (WMS).

Quality control data: Inspections, audits and compliance reports data were gathered in manufacturing and storage plants.

This is because the real-time data is combined with the historical data to forecast and take measures that prevent the possible disruption of the supply chain, including shortages in drug supply or shipping delays.

To enable controlled evaluation of autonomous decision performance, a discrete-time scenario-based simulation environment was constructed to represent a multi-echelon U.S. pharmaceutical supply chain consisting of manufacturing nodes,

distribution centers, and downstream demand points. The simulation captures the key operational flows relevant to resilience: production scheduling, inventory replenishment, shipment routing, and quality release constraints.

The simulation operates on a rolling planning horizon and incorporates stochastic disruption events that vary by scenario type (manufacturing downtime, logistics delays, and regulatory/quality holds). Demand is modeled as a time-varying process with baseline levels and surge periods to represent disruption-driven variability. Cold-chain integrity constraints and compliance escalation rules

are modeled as decision constraints rather than post-processing checks.

A baseline “human-driven” control policy is implemented as a rule-based decision cycle that reacts to disruptions after detection through periodic monitoring, manual escalation, and static safety-stock logic. The autonomous AI policy operates continuously, using streaming signals to trigger earlier detection and execute corrective actions in near real time. Both policies are evaluated under identical disruption scenarios and initial conditions to ensure comparability.

Table 2. Simulation Configuration Summary (Scenario-Based Evaluation)

Parameter	Value / Setting	Notes
Planning horizon	12 weeks (rolling weekly re-optimization)	Re-planning triggered at disruption events and scheduled review points
Supply chain nodes	1 manufacturing plant + 2 distribution centers (DCs) + 6 demand zones	Multi-echelon structure representing U.S. national distribution
Demand variability	±25% baseline variability; surge factor up to 1.5× during disruption windows	Captures seasonal spikes and shortage-driven demand volatility
Disruption probability	0.15 per week (per node) with severity levels: low/medium/high	Covers production delays, transport failures, and regulatory holds
Production lead time	7–14 days (SKU-dependent)	Reflects batch-based pharmaceutical manufacturing constraints
Cold-chain threshold	2–8°C compliance band; excursion alert if >15 minutes outside band	Cold-chain integrity enforced as a hard constraint in decision policies
Service level target	≥95% on-time delivery for critical SKUs	Used as resilience stability threshold for recovery time calculation
Baseline control policy	Rule-based human-driven response with periodic monitoring	Comparator for AI performance evaluation

B. Autonomous Artificial Intelligence Decision System.

The machine learning-based AI system created in this study analyzes the data obtained and makes independent decisions based on its analysis to optimize the pharmaceutical supply chain. The system is constructed based on two key elements predictive analytics and reinforcement learning.

Predictive Analytics: The system is based on the analysis of historical and real-time data in order to forecast possible disturbances in the supply chain. As an illustration, it will be able to forecast the probability of a shortage of drugs due to the production delay or due to the logistic bottlenecks due to transport data. Such predictions enable the system to get ready and respond in advance before some disruption takes place.

Reinforcement Learning: The AI system is based on reinforcement learning, which makes the decision-making of the system better over time. The system also is able to learn and adjust its decision-making strategy to future disruptions as it gets feedback on the consequences of its decisions, e.g. preventing a shortage or minimizing delays.

AI Decision Policy, State Representation, and Reward Function: The autonomous decision system is implemented as a two-layer intelligence stack. The first layer performs disruption sensing using predictive analytics models trained on historical and streaming operational signals (e.g., throughput variance, ETA deviations, temperature excursion alerts, inventory imbalance

indicators). The second layer executes response actions using a reinforcement learning (RL) decision policy that learns adaptive control strategies across disruption conditions.

The RL environment state includes: (i) inventory positions across nodes, (ii) production capacity and backlog indicators, (iii) shipment ETAs and route risk signals, (iv) quality release status and exception flags, and (v) demand urgency indicators for critical SKUs. The action space includes production resequencing, safety-stock reallocation, inventory balancing across distribution nodes, carrier reassignment, route rerouting, and shipment splitting or consolidation.

The reward function is defined as a weighted multi-objective objective prioritizing patient service continuity and compliance over cost. Specifically, the policy is penalized for stockout exposure, late deliveries of critical medicines, cold-chain risk increases, and compliance violations, while being rewarded for improved service levels, faster recovery, and efficient resource utilization. This design ensures that the autonomous policy optimizes resilience while remaining bound by regulatory and quality constraints.

Autonomous Optimization: When a disruption is forecasted, the system is able to automatically modify the production schedules, reroute deliveries or even modify inventory levels to eliminate the impact. Such decisions are not made manually but in real-time, and responses are faster and more efficient.




Figure 2. Autonomous AI Decision System Architecture for U.S. Pharmaceutical Supply Chains (Source: Author's own illustration.)

C. Simulation Scenarios and Testing:

Three simulation scenarios were developed to measure the effectiveness of the AI system, but these scenarios are based on typical disruption in pharmaceutical supply chains:

Scenario 1: Drug Shortages as a result of Production Delays: In this simulation, there is a disruption because of delays in production (e.g., equipment failure, shortages of raw materials). The AI system was to forecast the shortage and adjust the production timeline to make sure that the drugs were not out of stock.

Scenario 2: Transportation Failure Logistical Disruptions: In this scenario, a transportation failure (i.e. a strike or some form of natural disaster) causes delays in shipments. The AI system was charged with the responsibility of redirecting deliveries to other lines of delivery to reduce delays.

Scenario 3: Delays at the regulatory end of product approval: Here a regulatory delay (e.g., FDA approval) is what introduces a bottleneck in the supply chain. The AI system was to be able to parallel the production and shipping time to fit the new regulation timeline without jeopardizing the availability of the drugs.

All of these scenarios were experimented on two conditions, one being the use of AI-driven decision-making and another being the use of traditional human-driven decision-making. The performance of the AI-driven system was contrasted with the traditional system in terms of response time, cost efficiency and uptime.

D. Human Oversight and Compliance.

Even though the AI system is an independent one, human control is necessary especially to make sure that regulations are met. Pharmaceutical business is one of the most regulated business areas and it is essential that all the decisions of the AI system must

be in conformity to the industry standards, including those imposed by the FDA.

Prior to the execution of any critical decisions (e.g. changes to production schedules, adjustments to inventory, or shipment rerouting), the AI system notifies human experts. These professionals will ensure that AI-based decisions comply with the regulatory actions and that the safety and quality of the products comply with the standards. The presence of human control guarantees that the system will not jeopardize safety or breach regulatory quality and, on the contrary, enjoy the efficiency and speed of autonomous AI decision-making.

Given the high regulatory sensitivity of pharmaceutical supply chains, the system follows a bounded autonomy governance model. Under bounded autonomy, the AI can autonomously execute low-risk, reversible decisions (e.g., carrier reassignment, shipment rerouting within validated lanes, inventory balancing within approved substitution rules) while escalating high-impact decisions to human experts.

High-impact decision categories requiring human approval include: (i) any action affecting batch release timing or disposition status, (ii) actions that introduce cold-chain risk above threshold limits, (iii) decisions involving controlled substances or restricted distribution policies, and (iv) any decision requiring deviation closure or regulatory interpretation.

Each escalated decision is logged with an audit record containing the disruption trigger, the recommended action, expected impact on service and compliance KPIs, and an explainability summary (key drivers and constraints). This governance mechanism ensures that the AI system improves responsiveness while preserving patient safety, quality integrity, and regulatory compliance.




Figure 3. Bounded Autonomy Governance Model (Human-in-the-Loop Escalation)

(Source: Author’s own illustration.)

E. Metrics and Evaluation of Performance.

In order to measure the performance of the AI system, there were a number of key performance indicators (KPIs) that were measured during the simulations. It was these metrics that were employed to determine the usefulness of the AI system to deal with supply chain disruptions relative to the traditional techniques.

To ensure consistent evaluation across scenarios, KPIs are computed using standardized definitions. Response Time is measured as the time interval between disruption onset and the first corrective decision executed by the control policy. Recovery Time is measured as the time interval required for the system to return to stable service performance above the target service level. Stockout Exposure is measured as the cumulative hours in which inventory is below the minimum threshold for critical SKUs. On-Time Delivery is computed as the percentage of shipments delivered within the planned delivery window. Compliance Approval Rate is computed as the percentage of escalated high-impact decisions that receive human approval without violation flags. Total Cost Impact includes incremental logistics cost, expedited shipping cost, and inventory holding cost deltas relative to baseline.

The KPIs that were monitored were as follows:

1. **Response Time:** This is the duration of the AI system to detect and act on a supply chain disruption.
2. **Operational Uptime:** This is the percentage of time that the supply chain operated without interruptions as measured prior to and following AI-based interventions.
3. **Cost Savings:** The decrease in the operational expenses, such as shipping, production, and inventory expenses, which are achieved because of the decision-making optimization by the AI system.
4. **Compliance Rate:** This is the percentage of decisions that the AI system reached, which complied with regulatory requirements and human oversight submissions.
5. **Supply Chain Efficiency:** Expressed as a percentage of shipments that are delivered on time, inventory level accuracy, and optimization of the production schedule.




Figure 4. Scenario-Based Simulation Workflow and KPI Measurement

(Source: Author's own illustration.)

The metrics were contrasted with the AI-driven system and the human-driven systems to establish the comparative advantages and constraints of the autonomous AI in pharmaceutical supply chains.

7.0 Results

According to the evaluation based on the simulation, the autonomous AI decision systems have a significant positive effect on pharmaceutical supply-chain resilience in each of the disruption types (production delays, transportation interruptions, and regulatory/quality constraints). In all situations, the AI system saved time-to-detect disturbances and shortened time-to-recovery through automated recommendations and implementation of viable operational corrections (i.e., production resequencing, inventory rebalancing, and rerouting), and maintaining a human-approval gate whenever high-impact compliance and quality decisions were needed. These findings are consistent with the information that the analytics capacity is closely linked with the increased healthcare supply-chain operation and stability when appropriately integrated into the routine operations, and with the fact that the organizational preparedness and the industry pressure predetermine successful implementation of AI logistics.

In the production-delay case, the self-planning system learned about the presence of upstream constraints (risk of machine downtime, lag of raw-material) early on and advised to change the

scheduling and prioritization of lots. This minimized the number and length of stockout risk windows, facilitating the larger pharmacy-practice goal of securing continuity of access by patients. The distribution routes and carrier assignments in the transportation disruption scenario were re-optimized dynamically, which is in line with the value of the redesign of logistics based on optimization in healthcare delivery settings and the increasing importance of logistics automation as a force of responsiveness. In the regulatory/quality constraint case, the AI system had warehouse/QA indicators (temperature excursions, documentation exceptions, inspection results) and steered the decisions that needed regulatory judgment towards human consideration, which reflected best-practice priorities focused on the quality assurance of the warehouse and regulatory discipline.

In general, the most substantial benefits occurred in cases when the system was facilitated by interoperable, high-frequency data exchange among the stakeholders and in cases when the architecture was perceived as a constantly learning operational brain similar to adaptive, cognitively-informed digital-twin strategies to resilient healthcare services. In cases where data feeds were not complete or timely, AI recommendations were less aggressive and human-monitoring load was more, which is indicative of the fact that the advantageous effect of resilience is not only the ability of artificial intelligence but the level of maturity of digital infrastructure.

Table 3. Summary of Observed Effects of Autonomous AI by Disruption Scenario

Disruption scenario	Primary disruption signal(s)	Autonomous AI actions observed	Operational effect on resilience	Human oversight trigger
Production delays (manufacturing)	Equipment downtime risk; raw-material lag; throughput variance	Production resequencing; lot prioritization; safety-stock reallocation	Faster stabilization of supply; reduced shortage risk window	Changes affecting release timing/critical SKUs
Transportation/logistics disruption	Route blockage; carrier delay; missed delivery ETAs	Dynamic rerouting; carrier reassignment; shipment splitting/consolidation	Higher on-time delivery probability; reduced backlog propagation	Reroutes affecting cold-chain risk or controlled substances
Regulatory/quality constraints	QA exceptions; warehouse compliance alerts; documentation gaps	Hold-and-release logic; alternative DC allocation; compliant substitution proposals	Reduced compliance-related stoppages; maintained quality assurance	Any decision impacting regulatory status, labeling, or deviation closure
Demand surge/stock imbalance (downstream)	Sudden order spikes; regional stockout indicators	Inventory balancing across nodes; replenishment acceleration; prioritization rules	Improved service levels for critical medicines	Prioritization affecting patient-critical allocation policies

Table 4. KPI Comparison of Autonomous AI vs. Baseline Human-Driven Policy (Scenario-Based Simulation)

KPI	Baseline (Human-Driven)	Autonomous AI System	Improvement Direction
Disruption detection time (hours)	18	6	↓ Lower is better
Recovery time to stable operations (hours)	72	36	↓ Lower is better
Stockout exposure (hours per scenario)	24	8	↓ Lower is better
On-time delivery (%)	82	93	↑ Higher is better
Logistics cost impact (%)	14	6	↓ Lower is better
Compliance approval rate (%)	88	97	↑ Higher is better
Cold-chain exception rate (%)	6.2	2.1	↓ Lower is better

Statistical and Comparative Validation:

To validate robustness across stochastic disruption conditions, each scenario was executed across multiple simulation runs with randomized disruption timing and severity. KPI outcomes were aggregated and compared between the baseline and autonomous AI policies to assess consistent performance improvements. Across repeated runs, the autonomous AI policy demonstrated stable reductions in detection and recovery times and improved service-level outcomes, while maintaining compliance through bounded autonomy escalation. This confirms that the observed resilience improvements are not driven by a single favorable run but persist across variability typical of real-world pharmaceutical operations. In addition to reporting mean KPI values, variability across runs was assessed using standard deviation. Differences between baseline and autonomous policies were tested using a two-sided statistical test at a 95% confidence level to validate that observed improvements are not attributable to stochastic variation in disruption timing.

8.0 Discussion

The findings indicate that the use of autonomous AI decision systems is able to enhance the resilience in the U.S. pharmaceutical supply chains meaningfully by reducing the sense-decide-act cycle upon disruptions. At a practical level, the benefit of the system was the constant combination of the operational signals (manufacturing throughput, positions of inventory, logistics status, and quality events) with real time recommendations and actions, as opposed to

having the operational signals reviewed by a human at a periodic time interval or triggered by a rule. This is aligned with the fact that higher supply chain analytics ability is linked to superior healthcare supply chain performance, especially when analytics is integrated into operational processes and not seen as a reporting layer.

Disruption management of production: The capability of the AI to re-order schedules and the priority of lots minimized exposure to drug shortage windows in the production-delay situation. This is in accordance with healthcare innovations arguments that strong pharmacy practice and operational modernization is required to safeguard patient outcomes. Significantly, the benefits of the system were most pronounced when the system was able to access timely interoperable feeds between production planning and downstream demand signals. Where latency or fragmentation in data was present the model transitioned to conservative recommendations and this minimized the returns of optimizing and increased the human validation of the situation as a response.

Effects of logistics responsiveness and automation: In the transportation disruption case, AI enhanced continuity mainly with the help of re-optimization of routes and carriers, such as splitting shipments and active reassignments. The obtained benefits are directional in line with the power of optimization in rural healthcare provision and logistics planning, in which GIS-based routing and mobility redesign may aid in significant service responsiveness. They also correspond to the qualitative evidence that logistics automation is becoming a more viable option to more

responsive healthcare operations, although it requires organizational changes. In the pharmaceutical case, the most useful effect of the system was on avoiding local delays that caused stock imbalances across the entire network, which usually results in network failure.

Limitations of autonomy by quality and regulatory issues: It is also a major discovery that regulatory and quality requirements structure the degree of autonomy. The regulatory/quality scenario had the system working well when it considered compliance signals as first-class decision variables - e.g., automatically holding inventory where anomalies in the warehouse or the QA facility were detected, and escalating decisions that might change the release status or might need regulatory interpretation. This coincides with the focus on quality assessment of warehouses, best practices, technology, and regulatory suitability as primary controls to pharmaceutical logistics. The findings also suggest that the pattern of design that is most reliable is the bounded autonomy: the AI performs low stakes changes autonomously, but directs much more significant changes (e.g., release exceptions, substitutions, labeling implications) via a human approval gate. This form of governance assists in remaining safe at the same time gaining the benefits in terms of speed.

Impact moderation through organizational readiness: The findings also confirm the hypothesis that AI benefits in healthcare logistics are mediated by organizational readiness and external pressure. The AI generated greater continuity of services with fewer exceptions where processes, escalation pathways and data stewardship were mature in the simulation assumptions, whereas readiness was less, the AI logic generated more and more escalations and slower benefits realization, as hypothesized of AI value depending on readiness conditions, rather than model accuracy alone. Effectively, autonomy is not a light or dark switch, it is an ability that is proportional to governance, training and operational integration.

Sustainability implication and decision frameworks: The best performance of the AI was the capability to perform an objective function, where speed and cost were not the only factors considered, but also supply assurance and sustainability trade-offs (ex: reducing cold-chain risk, considering expedited shipping). Such a direction can be aligned with the frameworks of decision-making that have been suggested in vaccine supply chains, which underlines the focus on performance enhancement and simultaneously sustainability goals. In the case of pharmaceuticals, it means that the resilient autonomy must be developed as a multi-objective system: the availability and patient safety are the top-priority, and the cost and efficiency are maximized with the specified limitations.

Digital twins as an enabler: Given the architectural perspective, the findings are directed towards a digital twin-like operating model, in which the supply chain is continuously modeled, monitored, and optimally used adaptively. This is in line with suggestions for adaptive cognitive digital twins that would lead to the realization of resilient healthcare infrastructures and services. Independent decisions are made less unsafe and more understandable since they are checked against a constantly revised model of the restrictions (capacity, lead times, cold-chain limits, QA rules). This argument is supported by the fact that the rate of exceptions in the simulation was lower with a richer state

representation and the fact that resilience was enhanced when the system could think over an integrated model of operations instead of individual dashboards.

Intelligence in inventory and intelligent pharmacy extensions:

Lastly, the inventory balancing enhancements are consistent with the overall trend toward the IoT- based smart pharmacy and faster attention-based stock optimization models, which focus on proper sensing and quick anomaly detection to avoid stockouts and overstocking. This implies in the pharmaceutical supply chain that autonomous decision systems at the upstream are complementary with smart-pharmacy inventory intelligence at the downstream, with upstream system autonomy avoiding network shocks, and downstream system sensing enhancing local responsiveness and demand signal quality.

Implications: Taking together, these results suggest that autonomous AI can enhance the resilience of the pharmaceutical supply chain, the benefit of which is determined by (i) interoperable real-time data, (ii) a clear incorporation of compliance/quality constraints, and (iii) the organizational preparedness to automate and exception management. The practical implication is even deployment should be done in stages: initially there should be restricted autonomy in low-risk decision-making (routing, replenishment recommendations), which can be extended when governance, auditability and data quality are more developed.

The findings suggest that pharmaceutical organizations can achieve measurable resilience gains by deploying autonomous AI in phased maturity stages. In early deployments, firms should restrict autonomy to low-risk decisions such as dynamic routing recommendations and inventory balancing within validated constraints, while using structured escalation workflows for batch release and quality-sensitive decisions. As data interoperability and governance maturity improve, autonomy can be expanded to more complex production resequencing and multi-node optimization. For U.S. pharmaceutical supply chains, this approach supports national resilience priorities by reducing shortage risk exposure, improving responsiveness to disruption events, and strengthening continuity of patient access while preserving FDA-aligned compliance controls.

9.0 Conclusion

This paper has assessed the benefits of autonomous AI decision systems to enhance resilience in U.S pharmaceutical supply chains by enhancing early warning of disruptions, improving response time, and facilitating access to essential medications. The findings suggest that autonomous decision logic driven by combined real-time manufacturing, inventory, logistics, and quality information can minimize shortage exposure, enhance on-time delivery and minimize disruption cascades by making rapid schedule changes, inventory optimization, and distribution re-routing. These are in line with findings that embedded supply chain analytics can increase performance and reliability in the healthcare supply chain and that logistics automation can make healthcare supply chain responsive when change of operations is possible.

One of the main conclusions is that pharmaceutical autonomy must be bounded autonomy, but not complete unrestricted automation. Due to the fact that pharmaceutical logistics are closely linked to quality control and regulatory compliance, the safest and most

efficient design is an AI system that autonomously performs low-impact, reversible tasks, and increases high-impact decisions, in particular, those concerning the release of a product, quality exceptions, or interpretation of compliance, to human control. This hybrid model of governance ensures patient safety and regulatory integrity and still takes advantage of speed and efficiency.

Another thing that is established in the study is that the maturity of digital infrastructure is a strong determinant of resilience gains. High-frequency and interoperable data exchange also enhances the quality of AI decisions and exception workload, which is why connectivity and interoperability efforts are significant. Additionally, organizational preparedness mediates the achieved value: the more transparent operating guidelines and upgrading routes as well as human resource preparation firms are bound to transform AI suggestions into a quantifiable resilience effect.

Altogether, autonomous AI decision systems can be seen as a valid direction to safer pharmaceutical supply chains in the United States; although, to achieve success, negligent consideration of compliance controls, data governance, and human-in-the-loop validation is necessary. Future efforts are suggested to expand evaluation with real operation data, enlarge scenarios (cold-chain failure, multi-tier suppliers, and regional demand shock), and enhance digital-twin-like designs to enhance explainability, auditability, and safe scaling of autonomy in controlled pharmaceutical settings.

Future research should extend this work by incorporating real-world operational datasets from pharmaceutical manufacturers and distributors, evaluating additional disruption categories (e.g., cold-chain equipment failure, multi-tier supplier shortages, cyber disruptions), and improving explainability methods to strengthen auditability of autonomous decisions. Further validation using digital-twin-enabled environments can enhance trust, regulatory acceptance, and safe scaling of autonomy across controlled pharmaceutical settings.

References

1. Ambulkar, S., Blackhurst, J., & Grawe, S. (2015). Firm's resilience to supply chain disruptions: Scale development and empirical examination. *Journal of Operations Management*, 33–34, 111–122.
2. Amershi, S., Weld, D., Vorvoreanu, M., et al. (2019). Guidelines for human–AI interaction. In *Proceedings of the 2019 CHI Conference on Human Factors in Computing Systems (CHI '19)* (pp. 1–13). ACM.
3. Christopher, M., & Peck, H. (2004). Building the resilient supply chain. *The International Journal of Logistics Management*, 15(2), 1–14.
4. Choi, T.-M., Wallace, S. W., & Wang, Y. (2018). Big data analytics in operations management. *Production and Operations Management*, 27(10), 1868–1883.
5. Doshi-Velez, F., & Kim, B. (2017). Towards a rigorous science of interpretable machine learning. *arXiv preprint arXiv:1702.08608*.
6. Dubey, R., Gunasekaran, A., Childe, S. J., Wamba, S. F., Roubaud, D., & Foropon, C. (2020). Empirical investigation of data analytics capability and organizational flexibility. *International Journal of Production Research*, 58(3), 684–700.
7. Fox, E. R., Sweet, B. V., & Jensen, V. (2014). Drug shortages: A complex health care crisis. *Mayo Clinic Proceedings*, 89(3), 361–373.
8. Gunning, D., & Aha, D. (2019). DARPA's explainable artificial intelligence (XAI) program. *AI Magazine*, 40(2), 44–58.
9. Hosseini, S., Ivanov, D., & Dolgui, A. (2019). Review of quantitative methods for supply chain resilience analysis. *Transportation Research Part E: Logistics and Transportation Review*, 125, 285–307.
10. Ankit Sharma, Priyanshi Joshi. (2024). Artificial Intelligence Enabled Predictive Decision Systems for Supply Chain Resilience and Optimization. *Journal of Computational Analysis and Applications (JoCAAA)*, 33(08), 7460–7472. Retrieved from <https://eudoxuspress.com/index.php/pub/article/view/4715>.
11. ISO. (2015). ISO 9001:2015: Quality management systems—Requirements. International Organization for Standardization.
12. Ivanov, D. (2020). Predicting the impacts of epidemic outbreaks on global supply chains: A simulation-based analysis on the coronavirus outbreak (COVID-19/SARS-CoV-2) case. *Transportation Research Part E: Logistics and Transportation Review*, 136, 101922.
13. Ivanov, D., & Dolgui, A. (2020). Viability of intertwined supply networks: Extending the supply chain resilience angles towards survivability. *International Journal of Production Research*, 58(10), 2904–2915.
14. Ivanov, D., & Dolgui, A. (2021). OR-methods for coping with the ripple effect in supply chains during COVID-19 pandemic: Managerial insights and research implications. *International Journal of Production Economics*, 232, 107921.
15. Ankit Sharma. (2024). Cognitive AI for Autonomous Supply Chain Disruption Management: Architecture, Implementation, and Evaluation. *Journal of Computational Analysis and Applications (JoCAAA)*, 33(05), 3436–3459. Retrieved from <https://eudoxuspress.com/index.php/pub/article/view/4604>.
16. Ivanov, D., Sokolov, B., & Dolgui, A. (2014). The ripple effect in supply chains: Trade-off “efficiency-flexibility-resilience” in disruption management. *International Journal of Production Research*, 52(7), 2154–2172.
17. Iyengar, S., Hedman, L., Forte, G., & Hill, S. (2016). Medicine shortages: A commentary on causes and mitigation strategies. *BMC Medicine*, 14, 124.
18. Kritzing, W., Karner, M., Traar, G., Henjes, J., & Sihn, W. (2018). Digital twin in manufacturing: A categorical literature review and classification. *IFAC-PapersOnLine*, 51(11), 1016–1022.
19. LeCun, Y., Bengio, Y., & Hinton, G. (2015). Deep learning. *Nature*, 521, 436–444.
20. Mehralian, G., & Rasekh, H. R. (2019). The effects of supply chain management on drug shortages. *International Journal of Pharmaceutical and Healthcare Marketing*, 13(3), 280–299.
21. Min, H. (2010). Artificial intelligence in supply chain management: Theory and applications. *International Journal of Logistics Research and Applications*, 13(1), 13–39.
22. Mnih, V., Kavukcuoglu, K., Silver, D., et al. (2015). Human-level control through deep reinforcement learning. *Nature*, 518, 529–533.

23. Oroojlooyjadid, A., & Hajinezhad, D. (2019). A review of reinforcement learning in supply chain management. *Computers & Industrial Engineering*, 137, 106024.
24. Pettit, T. J., Fiksel, J., & Croxton, K. L. (2010). Ensuring supply chain resilience: Development of a conceptual framework. *Journal of Business Logistics*, 31(1), 1–21.
25. Ribeiro, M. T., Singh, S., & Guestrin, C. (2016). “Why should I trust you?” Explaining the predictions of any classifier. In *Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining (KDD '16)* (pp. 1135–1144). ACM.
26. Shneiderman, B. (2020). Human-centered artificial intelligence: Reliable, safe & trustworthy. *International Journal of Human–Computer Interaction*, 36(6), 495–504.
27. Sharma, A. (2019). Effect and impact of IoT (Internet of Thing) on supply chain management. *Journal of Emerging Technologies and Innovative Research (JETIR)*, 6(1). <https://doi.org/10.56975/jetir.v6i1.195290>.
28. Sutton, R. S., & Barto, A. G. (2018). *Reinforcement learning: An introduction* (2nd ed.). MIT Press.